Richmond Pharmacology, Community Research, and Fundación de Investigación de Diego, Puerto Rico has selected the ALPHADAS' early phase, e-source data capture system and site automation software suite which gives clinical research sites tools to accelerate and streamline their clinical trial operations and service. ALPHADAS is to be implemented initially in Richmond Pharmacology's MHRA Phase I Accredited facility, located in MayDay Hospital, London, UK as well as in Community Research's research facility, located in Cincinnati, Ohio, USA. ALPHADAS will be used in Fundación's new, purpose built 20,000 sq ft, research facility, located in San Juan, Puerto Rico. Fundacion de Investigacion new facility includes a 30 bed phase 1 unit, expanded ambulatory clinical trials space, and a bio-analytical laboratory.
ALPHADAS, is an e-Source, pro-active EDC system designed specifically for early phase clinical trials. Logos Technologies continues to invest in ALPHADAS, increasing its performance and functionality.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.